Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles

Table 4 Univariate and multivariate analyses for survival outcomes in patients who did not receive secondary debulking surgery

Characteristics	Progression-free survival					Overall survival
	Univariate analysis		Multivariate analysis			Univariate analysis		Multivariate analysis
	HR	95% CI	aHR	95% CI	P	HR	95% CI	aHR	95% CI	P
Age at initial diagnosis, years
≥55 vs. <55	0.75	0.51–1.11	0.714	0.483–1.057	0.093	0.80	0.42–1.54
Histologic type
Non-HGSC vs. HGSC	1.01	0.54–1.91				0.75	0.23–2.45
FIGO stage
IV vs. I-III	1.14	0.74–1.73				0.94	0.44–2.00	0.74	0.33–1.64	0.461
Primary treatment strategy
NAC vs. PDS	1.13	0.74–1.74				2.48	1.28–4.79
Results of initial debulking surgery
Residual tumor vs. CGR	1.15	0.79–1.68				1.22	0.63–2.34
Platinum-free interval, months
≥12 vs. 6–12	0.44	0.29–0.65	0.40	0.27–0.61	<0.001	0.37	0.19–0.71	0.37	0.19–0.72	0.004
CA-125 at 1st recurrence, IU/mL
≥90 vs. <90	1.60	1.09–2.35	1.88	1.26–2.82	0.002	1.77	0.92–3.42	1.78	0.91–3.47	0.090
Residual tumor on CT after #6
≥1 cm vs. <1cm	1.12	0.76–1.63	1.23	0.84–1.81	0.294	1.79	0.91–3.52	2.10	1.05–4.22	0.036
CA-125 after #6, IU/mL
≥12.5 vs. <12.5	1.58	1.08–2.32	1.18	0.79–1.76	0.412	1.36	0.72–2.58
Maintenance therapy
Yes vs. No	0.48	0.30–0.77	0.44	0.26–0.72	0.001	0.69	0.29–1.66	0.71	0.29–1.76	0.456
Extended chemotherapy
Yes vs. No	1.51	1.02–2.24	1.18	0.78–1.78	0.428	1.32	0.70–2.51	1.42	0.74–2.73	0.297

Abbreviations: aHR Adjusted HR, CA-125 Cancer antigen 125, CGR Complete gross resection, CI Confidence interval, CT Computed tomography, FIGO International Federation of Gynecology and Obstetrics, HGSC High-grade serous carcinoma, HR Hazard ratio

ISSN: 1471-2407